But, like Merck two weeks ago, GSK has failed to hit overall survival.

Two Kelun ADCs and two actinium-based radioconjugates start phase 1.

Merck ditches vibostolimab and favezelimab following huge pivotal programmes.

Data deteriorate, leaving cash-strapped Affimed relying on a post-hoc analysis and higher dosing.

Zelenectide looks uncompetitive versus Padcev in bladder cancer, while elsewhere a biomarker strategy beckons.

Quanta now has a “G12V-preferring” multi-KRAS asset on its clinical roster.

Lilly sheds more light on its second PI3Kα take, as Relay's combo data improve.

But the group is going up against the likes of Merck/Daiichi, Bristol Myers Squibb and BioNTech.

The company impresses investors, but money’s running short.

Menin, BTK and a Car-T skirmish featured over the ASH weekend.